Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123279 | 0.87 | ALDH1A1 (0.32) | ALDH1A1LMNAHSD17B10GLO1 | |
| SCHEMBL20115609 | 0.77 | — | — | |
| SCHEMBL12779381 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL6847856 | 0.74 | ALDH1A1 (0.36) | ALDH1A1LMNATDP1HSD17B10TP53 | |
| SCHEMBL10594010 | 0.71 | — | — | |
| SCHEMBL31134166 | 0.71 | NPSR1 (0.48) | ALDH1A1LMNATDP1HSD17B10GLO1 | |
| SCHEMBL15482412 | 0.71 | NPSR1 (0.48) | ALDH1A1LMNATDP1HSD17B10GLO1 | |
| SCHEMBL18446 | 0.70 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10GLO1CYP2D6 | |
| SCHEMBL3144067 | 0.68 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL497771 | 0.67 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118764-A1 | ALPHA-AMINO PATEAMINE A DERIVATIVES AND METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118764-A1 | ALPHA-AMINO PATEAMINE A DERIVATIVES AND METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | MCL1, PNMT, GNMT | ALDH1A1 552/4885LMNA 438/4885TDP1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.